Skip to main content

Peer Review reports

From: Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review

Original Submission
25 May 2022 Submitted Original manuscript
1 Jul 2022 Reviewed Reviewer Report - Suzanne Marks
22 Aug 2022 Reviewed Reviewer Report
6 Sep 2022 Author responded Author comments - Wendy A Lai
Resubmission - Version 2
6 Sep 2022 Submitted Manuscript version 2
14 Sep 2022 Author responded Author comments - Wendy A Lai
Resubmission - Version 3
14 Sep 2022 Submitted Manuscript version 3
4 Oct 2022 Reviewed Reviewer Report - Suzanne Marks
28 Oct 2022 Author responded Author comments - Wendy A Lai
Resubmission - Version 4
28 Oct 2022 Submitted Manuscript version 4
31 Oct 2022 Author responded Author comments - Wendy A Lai
Resubmission - Version 5
31 Oct 2022 Submitted Manuscript version 5
17 Nov 2022 Reviewed Reviewer Report - Suzanne Marks
23 Nov 2022 Author responded Author comments - Wendy A Lai
Resubmission - Version 6
23 Nov 2022 Submitted Manuscript version 6
Publishing
29 Nov 2022 Editorially accepted
7 Dec 2022 Article published 10.1186/s12889-022-14766-6

You can find further information about peer review here.

Back to article page